Literature DB >> 26378394

Inadequate hepcidin serum concentrations predict incident type 2 diabetes mellitus.

Raimund Pechlaner1, Günter Weiss2, Sukhvinder Bansal3, Manuel Mayr4, Peter Santer5, Barbara Pallhuber6, Marlene Notdurfter6, Enzo Bonora7, Johann Willeit1, Stefan Kiechl1.   

Abstract

BACKGROUND: Type 2 diabetes mellitus (T2DM) is closely associated with elevated body iron stores. The hormone hepcidin is the key regulator of iron homeostasis. Inadequately low hepcidin levels were recently reported in subjects with manifest T2DM. We investigated whether alterations of hepcidin levels precede the manifestation of T2DM and predict T2DM development independently of established risk conditions.
METHODS: This prospective population-based study included 675 subjects aged 50-89 years, 51.9% of whom were female. Hepcidin levels were measured by gold standard tandem mass spectrometry. Diabetes was diagnosed according to American Diabetes Association criteria, and incident diabetes was recorded between baseline in 2000 and 2010.
RESULTS: The baseline hepcidin-to-ferritin ratio in subjects that subsequently developed diabetes during follow-up was reduced on average by 29.8% as compared with subjects with normal glucose tolerance (95% confidence interval, -50.7% to -0.2%; p = 0.049). After adjustment for age, sex, and serum ferritin, higher hepcidin levels were associated with reduced risk of incident diabetes (hazard ratio per 1-unit higher log2 hepcidin, 0.80; 95% confidence interval, 0.64-0.98; p = 0.035; 33 events). Additional adjustment for established diabetes risk factors and determinants of hepcidin concentration did not appreciably change these results (HR, 0.81; 95% CI, 0.66-0.99). Likewise, inadequately low hepcidin levels were also detected in subjects with prevalent T2DM (n = 76).
CONCLUSIONS: Hepcidin levels that are inadequately low in relation to body iron stores are an independent predictor for incident T2DM and may contribute to diabetes-related tissue iron overload.
Copyright © 2015 John Wiley & Sons, Ltd. Copyright © 2015 John Wiley & Sons, Ltd.

Entities:  

Keywords:  hepcidin; iron; iron overload; risk factors; type 2 diabetes mellitus

Mesh:

Substances:

Year:  2015        PMID: 26378394     DOI: 10.1002/dmrr.2711

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  6 in total

1.  The Role of Insulin Therapy in Correcting Hepcidin Levels in Patients with Type 2 Diabetes Mellitus.

Authors:  Driton Vela; Jovica Leshoski; Elizabeta S Gjorgievska; Nikola Hadzi-Petrushev; Muharrem Jakupaj; Ramadan B Sopi; Mitko Mladenov
Journal:  Oman Med J       Date:  2017-05

Review 2.  The role of iron in host-microbiota crosstalk and its effects on systemic glucose metabolism.

Authors:  Jordi Mayneris-Perxachs; José María Moreno-Navarrete; José Manuel Fernández-Real
Journal:  Nat Rev Endocrinol       Date:  2022-08-19       Impact factor: 47.564

3.  Resistin hormone in diabetic kidney disease and its relation to iron status and hepcidin.

Authors:  Zhian Sherzad Hayder; Zrar Saleem Kareem
Journal:  Int Urol Nephrol       Date:  2020-03-15       Impact factor: 2.370

4.  Insulin treatment corrects hepcidin but not YKL-40 levels in persons with type 2 diabetes mellitus matched by body mass index, waist-to-height ratio, C-reactive protein and Creatinine.

Authors:  Driton Vela; Jovica Leshoski; Zana Vela; Muharrem Jakupaj; Mitko Mladenov; Ramadan B Sopi
Journal:  BMC Endocr Disord       Date:  2017-08-25       Impact factor: 2.763

Review 5.  Diabetes in HFE Hemochromatosis.

Authors:  James C Barton; Ronald T Acton
Journal:  J Diabetes Res       Date:  2017-02-26       Impact factor: 4.011

Review 6.  Differential regulation of hepcidin in cancer and non-cancer tissues and its clinical implications.

Authors:  Driton Vela; Zana Vela-Gaxha
Journal:  Exp Mol Med       Date:  2018-02-02       Impact factor: 8.718

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.